Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

被引:5
|
作者
Indini, Alice
Mandala, Mario
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Dept Internal Med, Milan, Italy
[2] Papa Giovanni XXIII Hosp, Dept Oncol & Hematol, Unit Med Oncol, Bergamo, Italy
关键词
Encorafenib; binimetinib; melanoma; braf; mek; targeted therapy; OPEN-LABEL; DABRAFENIB; VEMURAFENIB; SURVIVAL; MULTICENTER; TRAMETINIB; COLUMBUS; UPDATE; TRIAL;
D O I
10.1080/14740338.2020.1817376
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Approximately 40-50% of patients with cutaneous melanoma harbor point mutations inBRAF. BRAF and MEK inhibitors in combination are now a standard therapy for advancedBRAF(V600)-mutated melanoma. Nevertheless, survival rates with the combination are limited, highlighting the need for further therapeutic improvement and strategies to overcome primary and acquired resistance. Areas covered Encorafenib, a highly selective BRAF inhibitor, was developed in combination with binimetinib, a potent, selective allosteric MEK1/2 inhibitor, to improve efficacy and tolerability over other approved combo-targeted therapies. This novel combination shows peculiar pharmacodynamic properties which translate in a higher on-target potency and paradox index. Consistent survival improvements for encorafenib and binimetinib inBRAF(V600)-mutated melanoma have been confirmed in clinical trials, with over 4 years of median follow up. Expert opinion the favorable survival results and the attractive toxicity profile suggest that encorafenib and binimetinib combination is an intriguing standard option when targeted therapies are considered as first line treatment in BRAF mutated melanoma patients. In the near future, results from ongoing clinical trials will provide information on the use of this novel combination in specific situation, including as adjuvant treatment or as a combination strategy.
引用
收藏
页码:1229 / 1236
页数:8
相关论文
共 50 条
  • [41] Encorafenib (enco) plus binimetinib (bini) plus pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
    Schadendorf, Dirk
    Dummer, Reinhard
    Robert, Caroline
    Ribas, Antoni
    Sullivan, Ryan J.
    Panella, Timothy J.
    McKean, Meredith
    Santos, Edgardo S.
    Clancy, Jill S.
    Thakur, Mahgull Nazar
    Polli, Anna
    Di Pietro, Alessandra
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    Harding, James J.
    Catalanotti, Federica
    Munhoz, Rodrigo R.
    Cheng, Donavan T.
    Yaqubie, Amin
    Kelly, Nicole
    Mcdermott, Gregory C.
    Kersellius, Romona
    Merghoub, Taha
    Lacouture, Mario E.
    Carvajal, Richard D.
    Panageas, Katherine S.
    Berger, Michael F.
    Rosen, Neal
    Solit, David B.
    Chapman, Paul B.
    ONCOLOGIST, 2015, 20 (07): : 789 - 797
  • [43] Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Riely, G. J.
    Ahn, M-J.
    Clarke, J.
    Dagogo-Jack, I.
    Felip, E.
    Gelsomino, F.
    Goldman, J. W.
    Hussein, M.
    Johnson, M. L.
    Morgensztern, D.
    Nadal, E.
    Offin, M. D.
    Provencio Pulla, M.
    Ramalingam, S. S.
    Smit, E. F.
    Tsao, A. S.
    Alcasid, A.
    Usari, T.
    Wilner, K.
    Johnson, B.
    ANNALS OF ONCOLOGY, 2024, 35 : 1246 - 1247
  • [44] Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
    Berking, Carola
    Ascierto, Paolo A.
    Gogas, Helen J.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    de Groot, Jan Willem B.
    Yamazaki, Naoya
    Loquai, Carmen
    de Parseval, Laure A.
    Pickard, Michael
    Sandor, Victor
    Robert, Caroline
    Flaherty, Keith T.
    Dummer, Reinhard
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 45 - 45
  • [45] Matching-adjusted indirect comparison of nivolumab plus ipilimumab and BRAF plus MEK inhibitors for the treatment of BRAF-mutant treatment-naive advanced melanoma
    Atkins, Michael B.
    McDermott, David
    Tarhini, Ahmad
    Rael, Michael
    Gupte-Singh, Komal
    O'Brien, Elliot
    Ritchings, Corey
    Rao, Sumati
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Retrospective individual case reports on the treatment of patients with advanced BRAFV600-mutant malignant melanoma with encorafenib plus binimetinib (REMINISCENCE): focus on patients with brain metastases
    Debus, D.
    Rohrer, P.
    Grote, C.
    Kaehler, K. C.
    Koch, L.
    Reichenbach, F.
    Terheyden, P.
    Nguyen, V. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80
  • [47] Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
    Ester Simeone
    Antonio M. Grimaldi
    Lucia Festino
    Vito Vanella
    Marco Palla
    Paolo A. Ascierto
    BioDrugs, 2017, 31 : 51 - 61
  • [48] Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
    Simeone, Ester
    Grimaldi, Antonio M.
    Festino, Lucia
    Vanella, Vito
    Palla, Marco
    Ascierto, Paolo A.
    BIODRUGS, 2017, 31 (01) : 51 - 61
  • [49] Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study
    Smit, E.
    Ahn, M-J
    Dagogo-Jack, I.
    Felip, E.
    Gelsomino, F.
    Johnson, B.
    Johnson, M.
    Negrao, M. V.
    Offin, M.
    Ramalingam, S.
    Sanborn, R.
    Tsao, A.
    Wilner, K.
    Alcasid, A.
    Usari, T.
    Zhang, X.
    Riely, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S78
  • [50] Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
    Jameson-Lee, Max
    Ott, Patrick Alexander
    Luke, Jason J.
    Postow, Michael A.
    Poklepovic, Andrew Stewart
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)